Regulation of high-density lipoprotein by inflammatory cytokines: Establishing links between immune dysfunction and cardiovascular disease

Diabetes/Metabolism Research and Reviews

Volumn 26, Issue 2, 2010, Pages 90-99

  Haas, Michael J ^a   Mooradian, Arshag D ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Apolipoprotein A I; High density lipoprotein cholesterol; Pro inflammatory cytokines; Reverse cholesterol transport

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CYTOKINE; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE;

ACUTE PHASE RESPONSE; BIOGENESIS; CARDIOVASCULAR DISEASE; CHOLESTEROL TRANSPORT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; ENVIRONMENT; GENETICS; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFLAMMATION; METABOLIC DISORDER; OBESITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEPSIS;

ACUTE-PHASE REACTION; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; CYTOKINES; HUMANS; INFLAMMATION; LIPOPROTEINS, HDL; OBESITY; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 77950383271     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1057     Document Type: Review

References (114)

1. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
2. Brinton EA, Eisenberg S, Breslow JL. Human HDL cholesterol levels are determined by apoA-I fractional clearance rate,which correlates inversely with estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases, triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb 1994; 14: 707-720.
3. Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoprotein. J Int Med 2008; 263: 256-273.
4. Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA. Interleukin-1 activation of vascular endothelium. Effects on procoagulant activity and leukocyte adhesion. Am J Pathol 1985; 121: 394-403.
5. Dzau VJ, Braun-Dullaeus RC, Sedding SD. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 2002; 8: 1249-1256.
6. Jonasson L, Holm J, Skalli O, Gabbiani G, Hansson GK. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest 1985; 76: 125-131.
7. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulation of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Atherosclerosis 1986; 6: 131-138.
8. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP. The pathologic roles of interleukin-6 in human disease. Ann Int Med 1998; 128: 127-137.
9. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress, and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209-214.
10. Barath P, Fishbein MC, Cao J, Bernson J, Helfant RJ, Forrester JS. Detection and localization of TNF in human atheroma. Am J Cardiol 1989; 21: 1241-1251.
11. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990; 70: 427-451.
12. Vaddi K, Nicolini FA, Mehta P, Mehta JL. Increased secretion of tumor necrosis factor-alpha and interferon-gamma by mononuclear leukocytes in patients with ischemic heart disease: relevance in superoxide anion generation. Circulation 1994; 90: 694-699.
13. Kaartinen M, Penttila A, Kovanen P. Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF α. Circulation 1996; 94: 2787-2792.
14. Nicholls SJ, Dusting GJ, Cutri B, et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005; 111: 1543-1550.
15. Puranik R, Bao S, Nobecourt E, et al. Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis 2008; 196: 240-247.
16. Murphy AJ, Wollard KJ, Hoang A, et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 2008; 28: 2071-2077.
17. Bilgili S, Celebiler AC, Dogan A, Karaca B. Inverse relationship between adiponectin and plasminogen activator-1 in metabolic syndrome patients. Endocr Regul 2008; 42: 63-68.
18. Gomez-Hernandez A, Martin-Ventrua JL, Sanchez-Galan E, et al. Overexpression of COX-2, prostaglandin E synthase-1 and prostaglandin E receptors in blood mononuclear cells and plaque in patients with carotid atherosclerosis: regulation by nuclear factor-kappa B. Atherosclerosis 2006; 187: 139-149.
19. Ikonomidis I, Stamatelopoulos K, Lekakis J, Vamvakou GD, Kremastinos DT. Inflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery disease. Atherosclerosis 2008; 199: 3-11.
20. Barter P, McPherson YR, Song K, et al. Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia. J Clin Endocrinol Metab 2007; 92: 2041-2045.
21. Clarke R, Emberson JR, Breeze E, et al. Biomarkers of inflammation predict both vascular and non-vascular mortality in older men. Eur Heart J 2008; 29: 800-809.
22. Pineda J, Marin F, Marco P, et al. Premature coronary disease in young (age <45) subjects: interactions of lipid profile, thrombophilic and haemostatic markers. Int J Cardiol 2008; 136: 222-225.
23. Cabana VG, Shewmon VG, Scanu AM. Acute phase response in humans: correlation between plasma levels of C-reactive protein and lipoproteins. Arteriosclerosis 1985; 5: 535a.
24. Blackman JD, Cabana VG, Mazzone T. The acute-phase response and associated lipoprotein abnormalities accompanying lymphoma. J IntMed 1993; 233: 201-204.
25. Nofer JR, van der Giet M, Tolle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor SIP3. J Clin Invest 2004; 113: 569-581.
26. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 2005; 96: 2882-2891.
27. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995; 15: 1987-1994.
28. Calabresi L, Franceschini G, Sirtori CR, et al. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun 1997; 238: 61-65.
29. O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atheroslcerosis and their relation to intimal leukocyte content. Circulation 1996; 93: 672-682.
30. Harlan LM, Chan MA, Benedict SH. Two different modes of costimulation predispose human T lymphocytes to differential responses in the presence of HDL or oxidized LDL. Atherosclerosis 2007; 193: 309-320.
31. Solovjov D, Pluskota E, Plow E. Distinct roles for the alpha and beta subunits in the functions of integrin alpha M beta 2. J Biol Chem 2005; 280: 1336-1345.
32. Luegmayr E, Glantschnig H, Wesolowski GA, et al. Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/ lipoproteins. Cell Death Differ 2004; 11: S108-S118.
33. Gentili C, Tutolo G, Pianezzi A, Cancedda R, Descalzi Cancedda F. Cholesterol secretion and homeostasis in chondrocytes: a liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein A1 expression. Matrix Biol 2005; 24: 35-44.
34. NewtonCJ, RyanG, XieYX, et al. Statin-induced apoptosis of vascular endothelial cells is blocked by dexamethasone. J Endocrinol 2002; 174: 7-16.
35. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM. Mechanisms of disease: proatherogenic HDL- an evolving field. Nat Clin Pract Endocrinol Metab 2006; 2: 504-511.
36. Norata GD, Pirillo A, Catapano AL. Modified HDL: biological and physiopathological consequences. Nutr Metab Cardiovasc Dis 2006; 16: 371-386.
37. Yu R, Yekta B, Vakili L, et al. Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides. Curr Atheroscler Rep 2008; 10: 171-176.
38. CabanaVG, Lukens JR, RiceKS, Hawkins TJ, GetzGS. HDL content and composition in acute phase response in three species: triglyceride enrichment of HDL a factor in its decrease. J Lipid Res 1996; 37: 2662-2674.
39. Hu W, Abe-Dohmae S, Tsujita M, et al. Biogenesis of high density lipoprotein by serum amyloid A is dependent on ATP binding cassette transporter A-I in the liver in vivo. J Lipid Res 2008; 49: 386-393.
40. Betts JC, Cheshire JK, Akira S, Kishimoto T, Woo P. The role of NF-kappaB and NF-IL-6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6. J Biol Chem 1993; 268: 25624-25631.
41. Benditt EP, Eriksen N. Amyloid SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci U S A 1977; 74: 4025-4028.
42. Chau P, Fielding PE, Fielding CJ. Bone morphogenetic protein-1 (BMP-1) cleaves human proapolipoprotein A1 and regulates its activation for lipid binding. Biochemistry 2007; 46: 8445-8450.
43. Swenson TL, Brocia RW, Tall AR. Plasma cholesteryl ester transfer protein has binding sites for neutral lipids and phospholipids. J Biol Chem 1988; 263: 5150-5157.
44. Levels JH, Pajkrt D, Schultz M, et al. Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. Biochim Biophys Acta 2007; 1771: 1429-1438.
45. Huuskonen J, Olkkonen VM, Jauhiainen M, Metso J, Somerharju P, Ehnholm C. Acyl chain and headgroup specificity of human plasma phospholipid transfer protein. Biochim Biophys Acta 1996; 1303: 207-214.
46. Ng DS, Chu T, Esposito B, Hui P, Connelly PW, Gross PL. Paraoxonase-1 deficiency in mice predisposes to vasculars inflammation, oxidative stress, and thrombogenecity in the absence of hyperlipidemia. Cardiovasc Pathol 2008; 17: 226-232.
47. Jin W, Wang X, Miller JS, et al. Hepatic proprotein convertases modulate HDL metabolism. Cell Metab 2007; 6: 129-136.
48. White J, Guerin T, Swanson H, et al. Diabetic HDL-associated myristic acid inhibits acetycholine-induced nitric oxide generation by preventing the association of endothelial nitric oxide synthase with calmodulin. Am J Physiol Cell Physiol 2008; 294: C295-C305.
49. Gong M, Wilson M, Kelly T, et al. HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J Clin Invest 2003; 111: 1579-1587.
50. Horiuchi S, Sakamoto Y, Sakai M. Scavenger receptors for oxidized and glycated proteins. Amino Acids 2003; 25: 283-292.
51. Dessein PH, Joffe BI. Insulin resistance and impaired Beta cell function in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2765-2775.
52. Straub RH, Harle P, Starzi-Puttini P, Cutolo M. Tumor necrosis factor-neutralizing therapies improve altered hormone axes. Arthritis Rheum 2006; 54: 2039-2046.
53. Nishida K, Okada Y, Nawata M, Saito K, Tanaka Y. Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with Infliximab (IFX), an anti-TNF-alpha antibody. Endocr J 2008; 55: 213-216.
54. Park YB, Choi HK, Kim MY, et al. Effect of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002; 113: 1880193.
55. de Carvalho JF, Bonfa E, Borba EF. Systemic lupus erythematosus and "lupus dyslipoproteinemia.". Autoimmun Rev 2008; 7: 246-250.
56. Svenungsson E, Fei GZ, Jensen-Urstad K, de Faire U, Hamsten A, Frostegard J. TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 2003; 12: 454-461.
57. Bruce IN. Atherogenesis and autoimmune diseases: the model of lupus. Lupus 2005; 14: 687-690.
58. Escarcega RO, Garcia-Carrasco M, Fuentes-Alexandro S, et al. Insulin resistance, chronic inflammatory state, and the link with systemic lupus erythematosus-related coronary disease. Autoimmun Rev 2006; 6: 48-53.
59. Crow MK. Interferon path way activation in systemic lupus erythmatosus. Curr Rheumatol Rep 2005; 7: 463-468.
60. Cheung YF, Yung TC, Tam SC, Ho MH, Chau AK. Novel and traditional cardiovascular risk factors in children after Kawasaki disease: implications for premature atherosclerosis. J Am Coll Cardiol 2004; 43: 120-124.
61. Cheung YF, Tam SCF KO, Siow YL. Induction of MCP1, CCR2, and iNOS expression in THP-1 macrophages by serum of children late after Kawasaki disease. Pediatr Res 2005; 58: 1306-1310.
62. Katz J, Flugelman MY, Goldberg A, Heft M. Association between periodontal pockets and elevated cholesterol and low density lipoprotein. J Periodontol 2002; 73: 494-500.
63. Pussinin PJ, Jauhiainen M, Vikuna-Rautiainen T, et al. Periodontitis decreases the antiatherogenic potential of high density lipoprotein. J Lipid Res 2004; 45: 139-147.
64. Orem A, Yandi YE, Vanizor B, Cimsit G, Uydu HA, Malkoc M. The evaluation of autoantibodies against oxidatively modified low-density lipoprotein (LDL), susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total oxidant status, antioxidant enzyme activities, and endothelial dysfunction in patients with Behcet's disease. Clin Biochem 2002; 35: 217-224.
65. Haas MJ, Horani M, Gobal F, Wong NCW, Mooradian AD. Suppression of apolipoprotein AI gene expression in HepG2 cells by TNF α and IL-1β. Biochem Biophys Acta 2003; 1623: 120-128.
66. Beers A, Haas MJ, Wong NCW, Mooradian AD. Inhibition of apolipoprotein AI gene expression by tumor necrosis factor α: Roles for MEK/ERK and JNK signaling. Biochemistry 2006; 45: 2408-2413.
67. Wang K, Wan YJY. Nuclear receptors and inflammatory diseases. Exp Biol Med 2008; 233: 496-506.
68. Beigneux AP, Moser AH, Shigenega JK, Grunfeld C, Feingold KR. The acute phase response is associated with retinoid X receptor repression in rodent liver. J Biol Chem 2000; 275: 16390-16399.
69. Beigneux AP, Moser AH, Shigenega JK, Grunfeld C, Feingold KR. Sick euthyroid syndrome is associated with decreased TR expression and DNA binding in mouse liver. Am J Physiol Endocrinol Metab 2003; 284: E228-E236.
70. Morishima A, Ohkubo N, Maeda N, Miki T, Mitsuda N. NFκB regulates plasma apolipoprotein A-I and high density lipoprotein cholesterol through inhibition of peroxisome proliferator-activated receptor α. J Biol Chem 2003; 278: 38188-38193.
71. Del Rincon I, Williams K, SternMP, Freeman GL, Escalante A. High incidence of cardiovascular events in rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-2745.
72. Soubrier M, Jouanel P, Mathieu S, et al. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 2007; 75: 22-24.
73. McMahon M, Grossman J, Fitzgerald J, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54: 2541-2549.
74. Hahn BH, Grossman J, Ansell BJ, Skaggs BJ, McMahon M. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythrematosus and rheumatoid arthritis. Arthritis Res Ther 2008; 10: 213-224.
75. Khovidhunkit W, Memon RA, Feingold KR, Funfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J Infect Dis 2000; 181: S462-S472.
76. Navab B, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001; 21: 481-488.
77. Hume DA, Fairlie DP. Therapeutic targets in inflammatory disease. Curr Med Chem 2005; 12: 2925-2929.
78. Barish GD, Downes M, Alaynick WA, et al. A nuclear receptor atlas: macrophage activation. Mol Endocrinol 2005; 19: 2466-2477.
79. Valledor AF, Ricote M. Nuclear receptor signaling in macrophages. Biochem Pharmacol 2004; 67: 201-212.
80. Ricote M, Li AC, Wilson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
81. Hall JM, McDonnell DP. The molecular mechanisms underlying the proinflammatory actions of thiazolidinediones in human macrophages. Mol Endocrinol 2007; 21: 1756-1768.
82. Rigamonti E, Fontaine C, Lefebvre B, et al. Induction of CXCR2 receptor by peroxisome proliferator-activated receptor γ in human macrophages. Arterioscler Thromb Vasc Biol 2008; 28: 932-939.
83. Sirtori CR, Franceschini G. Effects of fibrates on serum lipids and atherosclerosis. Pharmacol Ther 1988; 37: 167-191.
84. Bard JM, Parra HJ, Camare R, et al. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism 1992; 41: 498-503.
85. Berthou L, Duverger N, Emmanuel F, et al. Opposite regulation of human versusmouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 1996; 11: 2408-2416.
86. Saladin R, Vu-Dac N, Fruchart JC, Auwerx J, Staels B. Transcriptional induction of rat liver apolipoprotein A-I gene expression by glucocorticoids requires the glucocorticoid receptor and a labile cell-specific protein. Eur J Biochem 1990; 239: 451-459.
87. Taylor AH, Raymond J, Dionne JM, et al. Glucocorticoid increases rat apolipoprotein A-I promoter activity. J Lipid Res 1996; 37: 2232-2243.
88. Martin G, Duez H, Blanquart C, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J Clin Invest 2001; 107: 1423-1432.
89. Qin S, Liu T, Kamanna VS, Kashyap ML. Pioglitazone stimulates apolipoprotein A-I productionwithout affecting HDL removal in HepG2 cells. Involvement of PPAR-α. Arterioscler Thromb Vasc Biol 2007; 27: 2428-2434.
90. Horani MH, Gobal F, Haas MJ, Wong NCW, Mooradian AD. Cyclooxygenase inhibition is associated with downregulation of apolipoprotein A-I promoter activity in cultured hepatoma cell line HepG2. Metabolism 2004; 53: 174-181.
91. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity 2008; 28: 477-487.
92. Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008; 14: 222-231.
93. Perkins ND. Integrating cell-signaling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007; 8: 49-62.
94. Kawai T, Akira S. Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 2007; 13: 460-469.
95. Mooradian AD, Haas MJ, Wehmeier KR, Wong NC. Obesity-related changes in high-density lipoproteinmetabolism. Obesity 2008; 16: 1152-1160.
96. Deleon MJ, Horani MH, Haas MJ, Wong NC, Mooradian AD. Effects of dehydroepiandrosterone on rat apolipoprotein AI gene expression in the human hepatoma cell line, HepG2. Metabolism 2002; 51: 376-379.
97. Wong NCW. The beneficial effects of plant sterols on serum cholesterol. Can J Cardiol 2001; 17: 715-721.
98. Hargrove GM, Junco A, Wong NCW. Hormonal regulation of apolipoprotein AI. J Mol Endocrinol 1999; 22: 103-111.
99. Araujo EP, De Sauza CT, Ueno M, et al. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinology 2008; 148: 5991-5997.
100. Liang H, Yin B, Zhang H, et al. Blockade of tumor necrosis factor (TNF) receptor type 1-mediated TNF-α signaling protected Wistar rats from diet-induced obesity and insulin resistance. Endocrinology 2008; 148: 2943-2951.
101. Konig H, Ponta H, Rahmsdorf HJ, Herrlich P. Interference between pathway-specific transcription factors: glucocorticoids antagonize phorbol ester-induced AP-1 activitywithout altering AP-1 site occupancy in vivo. EMBO J 1992; 11: 2241-2246.
102. Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFkB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 2000; 14: 2314-2329.
103. Caelles C, Gonzalez-Sancho JM, Munoz A. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev 1997; 11: 3351-3364.
104. Rider LG, Hirasawa N, Santini F, Beaven MA. Activation of the mitogen-activated protein kinase cascade is suppressed by low concentrations of dexamethasone in mast cells. J Immunol 1996; 157: 2374-2380.
105. Hadoke PWF, Iqbal J, Walker BR. Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Br J Pharmacol 2009; 156: 689-712.
106. De Bosscher K, Haegeman G. Latest perspectives on anti-inflammatory actions of glucocorticoids. Mol Endocrinol 2009; 23: 281-291.
107. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515-581.
108. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Ann Rev Immunol 2009; 27: 165-197.
109. Bleys J, Miller ER 3rd, Pastor-Barriuso R, Appel LJ, Guallar E. Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2006; 84: 880-887.
110. Wilcox BJ, Curb JD, Rodriquez BL. Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies. Am J Cardiol 2008; 101: 76D-86D.
111. Katsiki N, Manes C. Is there a role for supplemented antioxidants in the prevention of atherosclerosis? Clin Nutr 2009; 1: 3-9.
112. Chiesa G, Monteggia E, Marchesi M, et al. Recombinant apolipoprotein A-I(Milano) infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circul Res 2002; 90: 974-980.
113. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. J Am Med Assoc 2003; 290: 2292-22300.
114. Calabresi L, Sirtori CR, Paoletti R, Franceschini G. Recombinant apolipoprotein A-I Milano for the treatment of cardiovascular diseases. Curr Atheroscler Rep 2006; 8: 163-167.